FDA approval for novel breast cancer drug granted ahead of anticipated target date

Share this content:

the ONA take:

The US Food and Drug Administration granted accelerated approved for palbociclib (Ibrance) for the treatment of advanced breast cancer in postmenopausal women whose tumors do not express HER2 protein.

Palbociclib blocks molecules linked to cancer cell growth; it is intended for use in combination with letrozole. Designated as a breakthrough drug in 2014, approval was granted 2 months ahead of its April 13 target date. A 165-patient study showed that palbociclib slowed the progression of breast cancer.

Patients taking palbociclib and letrozole lived 20.2 months on average before their tumors worsened. The most common side effects reported were low white blood cell count, fatigue, nausea, hair loss, diarrhea, vomiting, and nerve damage. The drug is manufactured by Pfizer Inc.

How diabetes drugs may work against cancer
The FDA granted accelerated approved for palbociclib (Ibrance) for the treatment of advanced breast cancer.
The Food and Drug Administration approved Ibrance for women who have tumors that do not contain a protein known as HER-2. Ibrance, known generically as palbociclib, works by blocking molecules linked to cancer cell growth.
READ FULL ARTICLE From Medical Express
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs